Results 81 to 90 of about 25,638 (254)

Liraglutide, a Glucagon-Like Peptide-1 Analog, Increased Insulin Sensitivity Assessed by Hyperinsulinemic-Euglycemic Clamp Examination in Patients with Uncontrolled Type 2 Diabetes Mellitus

Journal of Diabetes Research, 2015
Aims. Glucagon-like peptide-1 (GLP-1) analog promotes insulin secretion by acting on pancreatic β-cells. This antihyperglycemic treatment for type 2 diabetes mellitus (DM) has attracted increased clinical attention not only for its antihyperglycemic ...
Hideaki Jinnouchi, Seigo Sugiyama, Akira Yoshida, Kunio Hieshima, Noboru Kurinami, Tomoko Suzuki, Fumio Miyamoto, Keizo Kajiwara, Kunihiko Matsui, Tomio Jinnouchi   +9 more
doaj   +1 more source

How the Sea Salt Chocolate Cookie Became a Thing: The Role of Flavor Pairing in Obesity

Obesity, EarlyView.
Proposed framework illustrating how flavor pairing and multisensory flavor architecture may sustain hedonic eating through enhanced palatability, reward preservation, delayed sensory‐specific satiety, and post‐ingestive signaling, thereby promoting excess energy intake and obesity risk.
Mohammed Ayyad, Eugene Kim
wiley   +1 more source

Liraglutide Attenuates Disease Severity in Experimental Autoimmune Encephalomyelitis by Modulating Splenic T Helper Cell Subsets

Brain and Behavior
Objective To investigate the therapeutic effects of liraglutide, a glucagon‐like peptide‐1 receptor agonist, on clinical progression and splenic T‐cell subsets in experimental autoimmune encephalomyelitis (EAE), a murine model of multiple sclerosis ...
Shuang Song, Bin Li, Ruoyi Guo, Yi Zhou, Yumei Xue, Li Guo   +5 more
doaj   +1 more source

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. [PDF]

, 2016
BACKGROUND: The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown.
Steinberg, W., Michael A. Nauck, Consoli, A., Pocock, Stuart, Peter Kristensen, Nissen, Steven E, Mette Stockner, Ravn, Lasse E., Stuart Pocock, Buse, John B., Marso, S., Nauck, M., Nissen, S., Stockner, M., Neil R. Poulter, . . . ], Nauck, Michael A, FILETTI, SEBASTIANO, LEADER Trial Investigators, Daniels, Gilbert H, Stockner, Mette, Lasse S. Ravn, Formoso, G., Nissen, Steven E., Brown-Frandsen, Kirstine, Steinberg, William M., Nauck, Michael A., Bergenstal, Richard M., Maranghi M., John B. Buse, Buse J, Johannes F. E. Mann, Daniels, G., Ravn, Lasse Steen, ?, ?, Poulter, Neil R, Gilbert H. Daniels, Mann, Johannes F. E., Buse, J., Ravn, Lasse S, Bergenstal, R., S., LEADER Steering Committee, Kristensen, Peter, Mann, Johannes F.E., Frandsen, Kirstine Brown, Mann, J., Ravn, L., Buse, John, Frandsen, K., Doggrell, Sheila, Pocock, S., Mann, Johannes FE, Zinman, B., William M. Steinberg, Buse, John B, Mann, Johannes F E, RIBICHINI, DANILO, Ravn, Lasse S., Zinman, Bernard, Bernard Zinman, Jaap, Alan, Hegedüs , Laszlo, Daniels G, Daniels, Gilbert H., Poulter, N., Marso, Steven P., Richard M. Bergenstal, Bergenstal, Richard M, Poulter, Neil R., Bergenstal R, REPACI, ANDREA, Steven P. Marso, Mann J, Liraglutide Effect and Action in Diabetes trial investigators, including Usman Malabu, Marso, Steven P, Kirstine Brown Frandsen, Sood, Amit, Steinberg, William M, Steven E. Nissen, GAMBINERI, ALESSANDRA, for the LEADER Steering Committee on behalf of the LEADER Trial Investigators [Study Investigator: . . ., BUSCEMI, Silvio, Kristensen, P.   +83 more
core   +3 more sources

Antitumoral activity of liraglutide, a new DNMT inhibitor in breast cancer cells in vitro and in vivo

, 2021
Breast cancer (BC) is the most frequently diagnosed female cancer and second leading cause of death. Despite the discovery of many antineoplastic drugs for BC, the current therapy is not totally efficient.
Picheth, Guilherme F, Jandrey, Elisa HF, de Campos, Felipe F, Manica, Graciele CM, Chequin, Andressa, Acco, Alexandra, de Noronha, Lucia, Sledz, Lucas R, Telles, Jose EQ, Goncalves, Marcos B, Valdameri, Glaucio, Moncada, Angie DB, Costa, Luiz E, Adami, Eliana R, de Lima, Lucas TF, et al.   +15 more
core   +1 more source

Incretin‐Based Therapies: A Testable Hypothesis Linking Incretin Signaling, Mitochondrial Redox, and OXPHOS Efficiency

Obesity, EarlyView.
ABSTRACT Objective Incretin‐based obesity therapies (IBTs), especially GLP‐1 receptor agonists (GLP‐1 RAs), effectively treat obesity and improve comorbidities. However, their impact on energy metabolism is unclear. A recent case of acute generalized muscle weakness in a patient with mitochondrial myopathy after tirzepatide exposure raises concerns ...
Bryn Falahee, Caroline M. Apovian, Nawfal Istfan   +2 more
wiley   +1 more source

Liraglutide and Βeta-Cell Function in Young Adults With Long-Standing Type 1 Diabetes and Residual C-Peptide: A Blinded, Randomized Controlled Trial. [PDF]

Diabetes Obes Metab
ABSTRACT Aims To evaluate the effect of liraglutide on residual beta‐cell function in adults with long‐standing type 1 diabetes (T1D) and detectable C‐peptide. Materials and Methods In this randomized, blinded, placebo‐controlled trial, 18 adults with T1D duration ≥ 5 years and detectable fasting C‐peptide were assigned to liraglutide or placebo for 52 
Caballero-Corbalán J, Lundkvist P, Espes D, Carlsson PO.   +3 more
europepmc   +2 more sources

GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway

, 2023
Jie Xiang,1 Liyan Qin,2 Jinling Zhong,3 Ning Xia,2 Yuzhen Liang3 1Department of Clinical Nutrition, The First Affiliated Hospital of Guangxi Medical University, Nanning, People’s Republic of China; 2Department of Geriatric Endocrinology, The First ...
Qin L, Liang Y, Xia N, Xiang J, Zhong J
core  

Reframing the role of glucagon‐like peptide 1 receptor agonists in cardiovascular medicine

ESC Heart Failure, Volume 12, Issue 2, Page 923-926, April 2025.
Riccardo M. Inciardi, Alvin Chandra, Ambarish Pandey, Marco Metra   +3 more
wiley   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists for Obstructive Sleep Apnea With and Without Continuous Positive Airway Pressure

Otolaryngology–Head and Neck Surgery, EarlyView.
Abstract Objective To evaluate glucagon‐like peptide 1 receptor agonists for obstructive sleep apnea compared with controls. Data Sources CINAHL, Cochrane Library, PubMed, and Scopus. Review Methods A PRISMA‐compliant search was conducted from database inception through October 2025.
Cali Loblundo, Sammy Y. Gao, Shaun A. Nguyen, Mohamed Abdelwahab   +3 more
wiley   +1 more source